<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02166177</url>
  </required_header>
  <id_info>
    <org_study_id>Treg Liver Trial</org_study_id>
    <nct_id>NCT02166177</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Regulatory T Cell Therapy in Liver Transplant Patients</brief_title>
  <acronym>ThRIL</acronym>
  <official_title>Pilot Study Evaluating the Safety and Efficacy Profile of Regulatory T Cell Therapy in Liver Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guy's and St Thomas' NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guy's and St Thomas' NHS Foundation Trust</source>
  <brief_summary>
    <textblock>
      'ThRIL' aims to explore the feasibility, safety and efficacy of TR002, a regulatory cell
      therapy, as adjunct immunosuppressive treatment in the context of liver transplantation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stage I: To evaluate the safety of administering TR002 to liver transplant recipients.

      Stage II: To evaluate the efficacy of TR002 administration in allowing for the
      discontinuation of immunosuppressive therapy in liver transplant recipients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">January 22, 2018</completion_date>
  <primary_completion_date type="Actual">January 22, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of dose limiting toxicities (DLTs)</measure>
    <time_frame>1 month after IMP administration</time_frame>
    <description>rate of adverse events qualifying as dose limiting toxicities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Graft Loss</measure>
    <time_frame>24 months</time_frame>
    <description>Rate of cellular rejection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunosuppressive doses</measure>
    <time_frame>24 months</time_frame>
    <description>total dose of immunosuppressive medication administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevention of acute and chronic rejection</measure>
    <time_frame>24 months</time_frame>
    <description>incidence of rejection episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute and Chronic Toxicity</measure>
    <time_frame>24 months</time_frame>
    <description>incidence of immunological reactions, biochemical disturbances</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver histology</measure>
    <time_frame>12 months</time_frame>
    <description>liver biopsy analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of successful immunosuppressive drug withdrawal</measure>
    <time_frame>24 months</time_frame>
    <description>total dose of immunosuppressive medication administered</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Immunological biomarkers</measure>
    <time_frame>12 months</time_frame>
    <description>immune monitoring analysis of blood samples investigating the effect of TR002 on blood cell immunophenotype</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>End-stage Liver Disease</condition>
  <arm_group>
    <arm_group_label>Autologous Regulatory T cell therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous regulatory T cell therapy infused intravenously (2 dose groups: low dose and high dose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Autologous regulatory T cell product</intervention_name>
    <description>Autologous regulatory T cell therapy infused intravenously (2 dose groups: low dose and high dose). The patients also receive rabbit Antithymocyte Globulin (rATG), tacrolimus, and sirolimus.</description>
    <arm_group_label>Autologous Regulatory T cell therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to give informed consent

          -  adult patients with end-stage liver disease listed for primary liver transplant;

          -  calculated MELD score â‰¤ 25 at time of transplantation

        Exclusion Criteria:

          -  HIV or RNA-positive Hepatitis C Virus infection;

          -  autoimmune liver disease

          -  previous organ transplant

          -  Ebstein Virus and/or Cytomegalovirus sero-negativity

          -  chronic use of systemic immunosuppressants

          -  hepatocellular carcinoma outside Milano criteria

          -  leukocytes &lt;1.5x10^9/L and/or platelets &lt;50x10^9/L.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giovanna Lombardi, PhD</last_name>
    <role>Study Director</role>
    <affiliation>King's College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kings College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>June 16, 2014</study_first_submitted>
  <study_first_submitted_qc>June 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2014</study_first_posted>
  <last_update_submitted>January 9, 2019</last_update_submitted>
  <last_update_submitted_qc>January 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

